Marina Kremyanskaya, MD PhD
-
- Position
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialties
- Cancer (Oncology)
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
-
Ruttenberg Treatment Center
1470 Madison Avenue
3rd Floor
New York, NY 10029
Phone: 212-241-6756212-241-6756
Marina Kremyanskaya, MD, PhD, is Assistant Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. She serves as the medical director for the inpatient oncology unit at The Mount Sinai Hospital, where she provides medical oversight in the management of hospitalized cancer patients. Dr. Kremyanskaya’s clinical focus is on acute myeloid leukemia (AML) and other myeloid malignancies such as myeloproliferative neoplasm (MPN), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), and other myeloid blood cancers.
She works as a part of a multidisciplinary team to provide high quality, patient-centered care and to ensure the best possible outcomes. Dr. Kremyanskaya is actively involved in the development of novel therapies for patients with MPN and AML, and is Principle Investigator on numerous clinical trials investigating better treatment options for these relatively rare conditions. She has authored multiple peer-reviewed publications and book chapters.
Certifications
Hematology
Medical Oncology
Clinical Focus
- Acute Myeloid Leukemia
- Essential Thrombocythemia
- Hematologic Malignancies
- Hematology
- Leukemia
- Leukocytosis / High White Blood Count
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Disorders
- Polycythemia Vera
- Thrombocytosis / High Platelets
Education
MD,PHD, University of Pennsylvania
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Hematology-Oncology
Mount Sinai Hospital
Language
English
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kremyanskaya during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Chimerix
- Protagonist Therapeutics, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.